⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13986559 | 0.81 | — | — | |
| SCHEMBL7218832 | 0.77 | — | — | |
| SCHEMBL3639631 | 0.77 | — | — | |
| SCHEMBL9716208 | 0.75 | GPR84 (0.32) | — | |
| SCHEMBL19689617 | 0.71 | — | — | |
| SCHEMBL601015 | 0.71 | — | — | |
| SCHEMBL600108 | 0.71 | — | — | |
| SCHEMBL11071521 | 0.71 | — | — | |
| SCHEMBL10650056 | 0.71 | ALDH1A1 (0.45) | — | |
| SCHEMBL21598423 | 0.71 | GPR84 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3935045-B1 | SYNTHESIS OF 4-AMINO-5-METHYL-1H-PYRIDIN-2(1H)-ONE (INTERMEDIATE IN THE SYNTHESIS OF THE MR ANTAGONIST FINERENONE) FROM 2-CHLORO-5-METHYL-4-PYRIDINAMINE VIA THE INTERMEDIATE 2-CHLORO-5-METHYL-4-PYRIDINEAMINE | BAYER AG (DE) | 2025-05-21 | — | — | EP | claimed |
| CN-118126037-A | Preparation method of non-neridrone bulk drug | 江苏海洋大学 | 2024-06-04 | — | — | CN | claimed |
| EP-3935044-B1 | PROCESS FOR PREPARING 4-AMINO-5-METHYLPYRIDONE | BAYER AG (DE) | 2023-04-12 | — | — | EP | claimed |
| EP-3935045-A1 | SYNTHESIS OF 4-AMINO-5-METHYL-1H-PYRIDIN-2(1H)-ON (INTERMEDIATE COMPOUND FOR THE SYNTHESIS OF THE MR ANTAGONIST FINERENONE) FROM 2-CHLORO-5-METHYL-4-NITRO-PYRIDINE-1-OXIDE USING THE INTERMEDIATE COMPOUND 2-CHLORO-5-METHYL-4-PYRIDINAMINE | Bayer Aktiengesellschaft (DE) | 2022-01-12 | — | — | EP | claimed |
| EP-3935044-A1 | PROCESS FOR PREPARING 4-AMINO-5-METHYLPYRIDONE | Bayer Aktiengesellschaft (DE) | 2022-01-12 | — | — | EP | claimed |
| EP-3935045-B1 | SYNTHESIS OF 4-AMINO-5-METHYL-1H-PYRIDIN-2(1H)-ONE (INTERMEDIATE IN THE SYNTHESIS OF THE MR ANTAGONIST FINERENONE) FROM 2-CHLORO-5-METHYL-4-PYRIDINAMINE VIA THE INTERMEDIATE 2-CHLORO-5-METHYL-4-PYRIDINEAMINE | BAYER AG (DE) | 2025-05-21 | — | — | EP | disclosed |
| EP-3935044-B1 | PROCESS FOR PREPARING 4-AMINO-5-METHYLPYRIDONE | BAYER AG (DE) | 2023-04-12 | — | — | EP | disclosed |
| EP-3935044-A1 | PROCESS FOR PREPARING 4-AMINO-5-METHYLPYRIDONE | Bayer Aktiengesellschaft (DE) | 2022-01-12 | — | — | EP | disclosed |
| EP-3935045-A1 | SYNTHESIS OF 4-AMINO-5-METHYL-1H-PYRIDIN-2(1H)-ON (INTERMEDIATE COMPOUND FOR THE SYNTHESIS OF THE MR ANTAGONIST FINERENONE) FROM 2-CHLORO-5-METHYL-4-NITRO-PYRIDINE-1-OXIDE USING THE INTERMEDIATE COMPOUND 2-CHLORO-5-METHYL-4-PYRIDINAMINE | Bayer Aktiengesellschaft (DE) | 2022-01-12 | — | — | EP | disclosed |
| EP-3935044-A1 | PROCESS FOR PREPARING 4-AMINO-5-METHYLPYRIDONE | Bayer Aktiengesellschaft (DE) | 2022-01-12 | — | — | EP | disclosed |
| WO-2020178177-A1 | PROCESS FOR PREPARING 4-AMINO-5-METHYLPYRIDONE | BAYER AKTIENGESELLSCHAFT (DE) | 2020-09-10 | — | — | WO | disclosed |
| EP-3174875-B1 | METHOD FOR THE PREPARATION OF (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1-6-NAPHTHYRIDINE-3-CARBOX-AMIDE AND THE PURIFICATION THEREOF FOR USE AS AN ACTIVE PHARMACEUTICAL INGREDIENT | Bayer Pharma AG (DE) | 2020-08-19 | — | — | EP | disclosed |
| US-6642254-B2 | Administering compounds, e.g., 8-methoxy-2-trifluoromethylquinoline-5-carboxylic acid (3,5-dichloro-1-oxypyridin-4-yl)amide for therapy of disease state that is capable of being modulated by inhibition of phosphodiesterase | DARWIN DISCOVERY, LTD. (GB) | 2003-11-04 | — | — | US | disclosed |
| US-20020183358-A1 | Heterocyclic compounds and their therapeutic use | DYKE HAZEL JOAN (GB) | 2002-12-05 | — | — | US | disclosed |
| US-6410559-B2 | 3,5-DISUBSTITUTED-(OXYPYRIDINE-4-YL)AMIDE DERIVATIVES USED AS PHOSPHODIESTERASE IV OR TUMOR NECROSIS FACTOR INHIBITOR TO TREAT INFLAMMATORY DISEASE OR AUTOIMMUNE DISEASE | DARWIN DISCOVERY, LTD. (GB) | 2002-06-25 | — | — | US | disclosed |
| US-20010025049-A1 | Heterocyclic compounds and their therapeutic use | DYKE HAZEL JOAN (GB) | 2001-09-27 | — | — | US | disclosed |
| US-6262070-B1 | E.G., 8-METHOXY-2-TRIFLUOROMETHYLQUINOLINE-5-CARBOXYLIC ACID(3,5-DICHLORO-1-OXYPYRIDIN-4-YL)AMIDE; TREATMENT OF CHRONIC OBSTRUCTIVE AIRWAYS DISEASE | DARWIN DISCOVERY LTD. (GB) | 2001-07-17 | — | — | US | disclosed |
| EP-1045845-A1 | N-OXIDES OF HETEROCYCLIC COMPOUNDS WITH TNF AND PDE-IV INHIBITING ACTIVITY | Darwin Discovery Limited (GB) | 2000-10-25 | — | — | EP | disclosed |
| WO-2000026208-A1 | N-OXIDES OF HETEROCYCLIC COMPOUNDS WITH TNF AND PDE-IV INHIBITING ACTIVITY | DARWIN DISCOVERY LIMITED (GB) | 2000-05-11 | — | — | WO | disclosed |
| US-4767698-A | PHOTOSTABILITY, HEAT RESISTANCE | AGFA-GEVAERT AKTIENGESELLSCHAFT (DE) | 1988-08-30 | — | — | US | disclosed |